RA
Live price temporarily unavailable.
Price history
Rani Therapeutics Holdings (RANI) is a Health Care company. Latest news and coverage below.
IPO: July 30, 2021 · $11.00 offering · NASDAQ · View IPO details →
Rani Therapeutics Holdings revenue & net income history (FY2020–FY2025)
RevenueNet income
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $462.0K | $2.72M | $0 | $0 | $1.03M | $1.63M |
| Growth (year over year) | — | +488.1% | −100.0% | — | — | +58.9% |
| Operating income | −$16.5M | −$51.6M | −$63.5M | −$66.1M | −$53.3M | −$38.3M |
| Operating margin | −3581.0% | −1899.1% | — | — | −5186.2% | −2346.0% |
| Net income | −$16.7M | −$8.33M | −$30.6M | −$34.0M | −$30.0M | −$29.7M |
| Net margin | −3615.4% | −306.6% | — | — | −2920.0% | −1817.1% |
| EPS (diluted) | — | −$0.43 | −$1.28 | −$1.33 | −$1.05 | −$0.45 |
| Balance sheet | ||||||
| Cash and equivalents | $73.1M | $117.5M | $27.0M | $5.86M | $3.76M | $18.6M |
| Total assets | $79.4M | $124.2M | $108.0M | $57.9M | $36.6M | $58.6M |
| Total liabilities | $8.04M | $2.64M | $34.0M | $32.5M | $33.1M | $17.1M |
| Long-term debt | $2.41M | $0 | $29.1M | $24.5M | $9.61M | $0 |
| Shareholders' equity | −$113.3M | $47.4M | $36.9M | $12.9M | $1.99M | $33.0M |
| Cash flow | ||||||
| Operating cash flow | −$15.0M | −$32.2M | −$46.5M | −$51.2M | −$35.5M | −$18.7M |
| Capital expenditure | $1.20M | $506.0K | $1.62M | $1.23M | $268.0K | $88.0K |
| Free cash flow | −$16.2M | −$32.8M | −$48.1M | −$52.5M | −$35.8M | −$18.8M |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $172.0K | $0 | $0 | — | $1.71M | $1.71M |
| Growth (year over year) | — | — | — | — | — | — | +893.0% | — |
| Operating income | −$11.8M | — | −$12.0M | −$10.5M | −$7.26M | — | −$8.34M | −$8.83M |
| Operating margin | — | — | −6984.3% | — | — | — | −488.2% | −516.9% |
| Net income | −$6.78M | — | −$7.26M | −$6.69M | −$5.41M | — | −$7.03M | −$7.39M |
| Net margin | — | — | −4223.3% | — | — | — | −411.8% | −432.7% |
| EPS (diluted) | −$0.24 | — | −$0.22 | −$0.18 | −$0.12 | — | −$0.04 | −$0.04 |
| Balance sheet | ||||||||
| Cash and equivalents | $4.28M | $3.76M | $10.1M | $10.2M | $4.14M | $18.6M | $9.64M | $4.87M |
| Total assets | $43.5M | $36.6M | $24.1M | $16.9M | $10.1M | $58.6M | $51.9M | $60.8M |
| Total liabilities | $37.8M | $33.1M | $29.5M | $26.1M | $22.1M | $17.1M | $16.3M | $12.9M |
| Long-term debt | $13.5M | $9.61M | $5.92M | $2.23M | $0 | $0 | — | — |
| Shareholders' equity | $3.12M | $1.99M | −$3.06M | −$5.58M | −$7.86M | $33.0M | $28.4M | $39.2M |
| Cash flow | ||||||||
| Operating cash flow | −$8.41M | — | −$8.15M | −$5.80M | −$5.06M | — | −$6.50M | −$9.03M |
| Capital expenditure | $125.0K | — | $51.0K | $37.0K | $0 | — | $15.0K | $32.0K |
| Free cash flow | −$8.54M | — | −$8.20M | −$5.83M | −$5.06M | — | −$6.51M | −$9.06M |
From Rani Therapeutics Holdings's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
About Rani Therapeutics Holdings
- Headquarters
- San Jose, California From SEC filings, Oct 2026
Recent News (2)
-
Rani Therapeutics’ pill platform accepted into FDA program
Rani Therapeutics’ pill platform accepted into FDA program
-
Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP) ~ Acceptance into ETP enables early FDA engagement to support development of the RaniPill® platform technology ~ ~ Acceptance into ETP enables early FDA engagement to support development of the RaniP…
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International